Regular electronic symptom questionnaires and feedback increased conversations about symptoms in Australia’s SWIFT haemodialysis trial, but did not demonstrate an improvement in the main quality-of-life outcome at 12 months. The finding separates collecting and discussing patient information from demonstrating a health benefit from the system around it. The results are currently reported in a conference abstract, rather than a full final trial paper examined here. ASN Kidney Week results abstract
For teams introducing patient-reported outcome measures, the trial offers a concrete comparison between the information pathway and the outcome it was intended to change.
What the intervention added to usual care
SWIFT compared three-monthly symptom assessment and feedback with usual care. The intervention used the Integrated Palliative Outcome Scale–Renal, or IPOS-Renal, to capture patients’ symptoms and return scores to patients and clinicians alongside guidance for managing them.
The published protocol describes people completing questionnaires using tablets during in-centre dialysis visits. It is a full description of the planned design, not the final results report. Its recruitment targets should not be substituted for the numbers ultimately reported. Original SWIFT protocol
The 2026 abstract reports 2,412 patients across 92 units grouped into 56 randomized clusters. People, units and clusters are different denominators. The study is about in-centre haemodialysis; it is not evidence that a home-dialysis monitoring app improves outcomes.
The primary result did not show an improvement
The primary outcome was health-related quality of life measured using the EQ-5D-5L instrument. At 12 months, the reported adjusted difference between groups was 0.01, with a 95% confidence interval from −0.02 to 0.04.
For the separate SONG-HD fatigue measure, the difference was 0.04, with a 95% confidence interval from −0.23 to 0.31. Both intervals include zero; the reported comparisons did not establish an improvement on those measures. They do not prove that every possible effect of symptom monitoring is exactly zero. Outcome definitions and estimates
The quality-of-life and fatigue scores also have different scales. Their numerical differences cannot be compared as if a larger decimal represented a larger common health benefit.
More conversation was a different outcome
The researchers reported more patient-described symptom consultations and perceived changes in management in the intervention group. Those process findings can coexist with a null primary outcome. A conversation is a change in the care interaction; an improvement in the trial’s quality-of-life measure is another test.
The abstract also reports that clinicians viewed feedback scores 71% of the time at baseline, falling to 60% at 12 months. That is a measure of clinician feedback viewing, not a patient adherence rate. The decline is relevant to implementation, but it does not by itself explain why the main outcome did not improve.
The University of Sydney’s account emphasizes the ability to collect patient-reported information across a geographically diverse dialysis population and the need for services able to respond to symptoms. It describes the same trial, not independent confirmation of its effect. Trial team’s service-context account
A questionnaire is part of an intervention, not its whole mechanism
The result is useful because the comparison goes beyond whether a digital questionnaire can be completed. It tests a package of recurring measurement, feedback and guidance against usual care, with a specified health outcome and follow-up period.
Our digital dialysis peer-support analysis examines a different intervention and a different set of participation questions. The SUPPORT+ cancer-care trial concerns another patient population and a supported response pathway. Their results cannot be transferred to SWIFT simply because all three involve digital support.
The full SWIFT results will be needed to assess detailed analyses and unresolved implementation questions. What the reported comparison already establishes is narrower: more symptom conversation did not translate into a demonstrated quality-of-life or fatigue improvement in the measured 12-month outcomes.